Vector Science and Therapeutics (TSXV:PAIN) Net Current Asset Value: C$0.15 (As of Feb. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:PAIN Vector Science and Therapeutics Corp TSXV:PAIN
14 GF Score
Price C$1.55
View Full Analysis

What is Vector Science and Therapeutics Net Current Asset Value?

Vector Science and Therapeutics TSXV:PAIN -4.32% 14 Net Current Asset Value is C$0.15 as of Feb. 2026. GuruFocus rates TSXV:PAIN with a GF Score™ of 14/100. Among 566 Medical Devices & Instruments companies, Vector Science and Therapeutics ranks worse than 75.27% on this metric.

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Vector Science and Therapeutics's net current asset value per share for the quarter that ended in Feb. 2026 was C$0.15.

The historical rank and industry rank for Vector Science and Therapeutics's Net Current Asset Value or its related term are showing as below:

TSXV:PAIN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0   Med: 0   Max: 10.8
Current: 10.33

During the past 2 years, the highest Price-to-Net-Current-Asset-Value Ratio of Vector Science and Therapeutics was 10.80. The lowest was 0.00. And the median was 0.00.

TSXV:PAIN's Price-to-Net-Current-Asset-Value is ranked worse than
75.27% of 566 companies
in the Medical Devices & Instruments industry
Industry Median: 4.815 vs TSXV:PAIN: 10.33

Vector Science and Therapeutics  (TSXV:PAIN) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Vector Science and Therapeutics Net Current Asset Value Related Terms


Vector Science and Therapeutics Net Current Asset Value Historical Data

* Premium members only.

The historical data trend for Vector Science and Therapeutics's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vector Science and Therapeutics Net Current Asset Value Chart

Vector Science and Therapeutics Annual Data
Trend Aug24 Aug25
Net Current Asset Value
0.00 0.43

Vector Science and Therapeutics Quarterly Data
Aug24 Nov24 Aug25 Nov25 Feb26
Net Current Asset Value 0.00 0.00 0.43 0.22 0.15

TSXV:PAIN vs ABT, SYK, MDT: Net Current Asset Value Comparison

For the Medical Devices subindustry, Vector Science and Therapeutics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vector Science and Therapeutics Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vector Science and Therapeutics's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Vector Science and Therapeutics's Price-to-Net-Current-Asset-Value falls into.


TSXV:PAIN
14GF Score
Vector Science and Therapeutics Corp TSXV:PAIN
Net Current Asset Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vector Science and Therapeutics Net Current Asset Value Calculation

Vector Science and Therapeutics's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Aug. 2025 is calculated as

Net Current Asset Value Per Share(A: Aug. 2025 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(4.114-1.766-0-0)/5.500
=0.43

Vector Science and Therapeutics's Net Current Asset Value (NCAV) per share for the quarter that ended in Feb. 2026 is calculated as

Net Current Asset Value Per Share(Q: Feb. 2026 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(2.1-1.29-0-0)/5.500
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Current Asset Value of C$0.15 mean?
Vector Science and Therapeutics (TSXV:PAIN) has a Net Current Asset Value of C$0.15 as of Feb. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Vector Science and Therapeutics and its competitors. According to the industry distribution chart, Vector Science and Therapeutics ranks #426 out of 566 companies in the Medical Devices & Instruments industry, placing it in the top 75.3%.
Is Vector Science and Therapeutics' Net Current Asset Value too high?
Vector Science and Therapeutics' current Net Current Asset Value is C$0.15. Based on the distribution chart, Vector Science and Therapeutics ranks #426 out of 566 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Vector Science and Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Vector Science and Therapeutics' Net Current Asset Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vector Science and Therapeutics ranks #426 out of 566 companies for Net Current Asset Value. This places Vector Science and Therapeutics in the lower half of its industry. The industry median Net Current Asset Value is 4.82. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 4.82, based on 566 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Vector Science and Therapeutics and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 4.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vector Science and Therapeutics's current Net Current Asset Value is C$0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vector Science and Therapeutics stock overvalued right now?
Vector Science and Therapeutics (TSXV:PAIN) has a current Net Current Asset Value of C$0.15. The current Net Current Asset Value is C$0.15. Vector Science and Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Vector Science and Therapeutics (TSXV:PAIN), the current Net Current Asset Value is C$0.15 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vector Science and Therapeutics Business Description

Vector Science and Therapeutics Corp develops novel biomechanical devices and active transdermal drug and peptide delivery platforms to equip clinicians with non-systemic, localized interventions targeting a broad cross-section of diseases and conditions where systemic delivery of interventions compromises the therapeutic effect or introduces unacceptable harm.
14GF Score

Get the complete analysis for TSXV:PAIN

Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$1.55
Price